Common use of Unilateral Termination Clause in Contracts

Unilateral Termination. Either ICD or Collaborator may unilaterally terminate this CRADA at any time by providing written notice at least sixty (60) days before the desired termination date. ICD may, at its option, retain funds transferred to ICD before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator terminates this Agreement before the completion of all approved or active Protocol(s), then Collaborator will supply enough Test Article (and Placebo, if applicable) to complete these Protocol(s) unless termination is for safety concerns.

Unilateral Termination. Either ICD IC or Collaborator may unilaterally terminate this CRADA at any time by providing written notice at least sixty (60) days before the desired termination date. ICD IC may, at its option, retain funds transferred to ICD IC before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator terminates this Agreement before the completion of all approved or active Protocol(s), then Collaborator will supply enough Test Article (and Placebo, if applicable) to complete these Protocol(s) unless termination is for safety concerns.

Unilateral Termination. Either ICD IC or Collaborator may unilaterally terminate this CRADA at any time by providing written notice at least sixty (60) days before the desired termination date. ICD IC may, at its option, retain funds transferred to ICD IC before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator terminates this Agreement before the completion of all approved or active Protocol(s), then Collaborator will supply enough Test Article (and Placebo, if applicable) to complete these Protocol(s) unless termination is for safety concerns.

Unilateral Termination. Either ICD IC or Collaborator may unilaterally terminate this CRADA at any time by providing written notice at least sixty (60) days before the NCI DCTD CRADA model adopted October 14, 2011 Case Ref. No. 00-0-00000 Page 24 of 33 Confidential desired termination date. ICD IC may, at its option, retain funds transferred to ICD IC before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator terminates this Agreement before the completion of all approved or active Protocol(s), then Collaborator will supply enough Test Article (and Placebo, if applicable) to complete these Protocol(s) Investigational Agent in Collaborator’s inventory unless termination is for safety concerns.

Unilateral Termination. Either ICD or Collaborator may unilaterally terminate this CRADA at any time by providing written notice at least sixty (60) days before the desired termination date. ICD may, at its option, retain funds transferred to ICD before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator terminates this Agreement before the completion of all approved or active Protocol(s), then Collaborator will supply enough Test Article (and Placebo, if applicable) to complete these Protocol(s) unless termination is for safety concerns. In the event of termination of the CRADA prior to the expiration date, or upon expiration of the CRADA, Collaborator will continue to provide cross reference letters to its DMFs and/or INDs in order to enable ICD to complete the studies approved, initiated or active.

Unilateral Termination. Either ICD or Collaborator may unilaterally terminate this CRADA at any time by providing written notice at least sixty (60) days before the desired termination date. ICD may, at its option, retain funds transferred to ICD before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator terminates this Agreement before the completion of all approved or active Protocol(s), then Collaborator will supply enough Test Article (and Placebo, if applicable) to complete these Protocol(s) unless termination is for safety concerns.

Unilateral Termination. Either ICD or Collaborator may unilaterally terminate this CRADA at any time by providing written notice at least sixty (60) days before the desired termination date. ICD may, at its option, retain funds transferred to ICD before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator terminates this Agreement before the completion of all approved or active Protocol(s), then Collaborator will supply enough Test Article (and Placebo, if applicable) to complete these Protocol(s) unless termination is for safety concerns. In the event of termination of the CRADA prior to the expiration date, or upon expiration of the CRADA. Collaborator will continue to provide cross reference letters to its DMFs and/or INDs in order to enable ICD to complete the studies approved, initiated or active.

Unilateral Termination. Either ICD IC or Collaborator may unilaterally terminate this CRADA at any time by providing written notice at least sixty (60) days before the desired termination date. ICD IC may, at its option, retain funds transferred to ICD IC before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator terminates this Agreement before the completion of all approved or active Protocol(s), then Collaborator will supply enough Test Article Investigational Agent (and Placebo, if applicable) to complete these Protocol(s) unless termination is for safety concerns.

Unilateral Termination. Either ICD or Collaborator may unilaterally terminate this CRADA at any time by providing written notice at least sixty ninety (6090) days before the desired termination date. ICD may, at its option, retain funds transferred to ICD before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator terminates this Agreement before the completion of all approved or active Protocol(s), then Collaborator will supply enough Test Article (and Placebo, if applicable) to complete these Protocol(s) unless termination is for safety concerns.. Amend Section 10.6 to read as follows:

Unilateral Termination. Either ICD IC or Collaborator may unilaterally terminate this CRADA at any time by providing written notice at least sixty (60) days before the desired termination date. ICD IC may, at its option, retain funds transferred to ICD IC before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator terminates this Agreement before Reasons for unilateral termination may include but are not limited to failure to meet or complete project milestones, failure to disclose all safety and toxicity data related to the completion of all approved or active Protocol(s), then Collaborator will supply enough Test Article (and Placebo, if applicable) to complete these Protocol(s) unless termination is for safety concernsproject.

Unilateral Termination. Either ICD NCI or Collaborator may unilaterally terminate this CRADA at any time by providing written notice at least sixty (60) days before the desired termination date. ICD NCI may, at its option, retain funds transferred to ICD NCI before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator terminates this Agreement before the completion of all approved or active Protocol(s), then Collaborator will supply enough Test Article Investigational Agent (and Placebo, if applicable) and enough CRADA Materials (if applicable) to complete these Protocol(s) unless termination is for safety concerns.

Unilateral Termination. Either ICD IC or Collaborator may unilaterally terminate this CRADA at any time by providing written notice at least sixty (60) days before the desired termination date. ICD IC may, at its option, retain funds transferred to ICD IC before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator terminates this Agreement before the completion of all approved or active Protocol(s), then Collaborator will supply enough Test Article (and Placebo, if applicable) necessary to complete these Protocol(s) unless termination is for safety concerns.